What's Happening?
The National Institute for Health and Care Excellence (NICE) has issued preliminary guidance rejecting the use of Genmab's Tivdak (tisotumab vedotin) for treating cervical cancer within the NHS. Tivdak, an antibody-drug conjugate targeting tissue factor,
was approved by the UK Medicines and Healthcare products Regulatory Agency as an alternative to chemotherapy for patients with recurrent or metastatic cervical cancer. Despite its clinical benefits, NICE raised concerns about the economic model proposed by Genmab, questioning the cost-effectiveness of the drug for NHS use. The decision is based on the lack of an approved list price and the economic estimates exceeding acceptable thresholds.
Why It's Important?
This decision impacts patients with advanced cervical cancer, who have limited treatment options. Tivdak's rejection by NICE highlights the challenges pharmaceutical companies face in balancing clinical efficacy with economic viability for public health systems. The decision also underscores the importance of cost-effectiveness in healthcare resource allocation, particularly within the NHS. For Genmab, this represents a setback in its efforts to expand Tivdak's market presence in Europe, potentially affecting its financial performance and strategic plans.
